245 related articles for article (PubMed ID: 33796913)
21. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
[TBL] [Abstract][Full Text] [Related]
22. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
23. Radiological and clinical features of large consolidative-type pulmonary invasive mucinous adenocarcinoma.
Chen J; Qi L; Wang J; Xue L; Xue Q; Jia J; Zhang G; Liu J; Li F; Cui S
Clin Respir J; 2024 Mar; 18(3):e13743. PubMed ID: 38529681
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
[TBL] [Abstract][Full Text] [Related]
27. GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations.
Nakajima N; Yoshizawa A; Nakajima T; Hirata M; Furuhata A; Sumiyoshi S; Rokutan-Kurata M; Sonobe M; Menju T; Miyamoto E; Chen-Yoshikawa TF; Date H; Haga H
Histopathology; 2018 Jul; 73(1):38-48. PubMed ID: 29469192
[TBL] [Abstract][Full Text] [Related]
28. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
Sullivan I; Salazar J; Arqueros C; Andrés M; Sebio A; Majem M; Szafranska J; Martínez E; Páez D; López-Pousa A; Baiget M; Barnadas A
Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
[TBL] [Abstract][Full Text] [Related]
29. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
30. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
31. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
32. Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases.
Chang WC; Zhang YZ; Wolf JL; Hermelijn SM; Schnater JM; von der Thüsen JH; Rice A; Lantuejoul S; Mastroianni B; Farver C; Black F; Popat S; Nicholson AG
Histopathology; 2021 Feb; 78(3):434-444. PubMed ID: 32810914
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
34. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Chang JC; Offin M; Falcon C; Brown D; Houck-Loomis BR; Meng F; Rudneva VA; Won HH; Amir S; Montecalvo J; Desmeules P; Kadota K; Adusumilli PS; Rusch VW; Teed S; Sabari JK; Benayed R; Nafa K; Borsu L; Li BT; Schram AM; Arcila ME; Travis WD; Ladanyi M; Drilon A; Rekhtman N
Clin Cancer Res; 2021 Jul; 27(14):4066-4076. PubMed ID: 33947695
[TBL] [Abstract][Full Text] [Related]
36. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
[TBL] [Abstract][Full Text] [Related]
38. Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings.
Nie K; Nie W; Zhang YX; Yu H
Cancer Imaging; 2019 Jul; 19(1):47. PubMed ID: 31292000
[TBL] [Abstract][Full Text] [Related]
39. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
[TBL] [Abstract][Full Text] [Related]
40. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M
Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
